Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 11:55 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 30 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Adnexal Mass Clear all
Terminated Phase 1Phase 2 Interventional Results available

A Phase Ib/II Study of the Combination of BYL719 Plus AMG 479 in Adult Patients With Selected Solid Tumors

NCT01708161
View directory record Official record
Conditions
PIK3CA Mutated Advanced Solid Tumors, PIK3CA Amplified Advanced Solid Tumors
Interventions
BYL719, AMG 479
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
4
States / cities
Los Angeles, California • Boston, Massachusetts • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 12, 2018 · Synced Jul 22, 2026, 11:55 AM EDT
Terminated Phase 2 Interventional Results available

Comparing Intrathecal Morphine and Intraoperative Lidocaine Infusion to Epidural Anesthesia With Postoperative PCA for Patients Undergoing Exploratory Laparotomy

NCT05017246
View directory record Official record
Conditions
Cancer Debulking, Enlarged Uterus, Fibroid Uterus, Adnexal Mass
Interventions
Bupivacaine, Morphine, Lidocaine
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older · Female only
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 30, 2025 · Synced Jul 22, 2026, 11:55 AM EDT
Completed Phase 1 Interventional

Folate Receptor in Diagnosing Ovarian Cancer Using Serum Samples From Patients With Newly Diagnosed Pelvic Mass or Previously Diagnosed Ovarian Cancer

NCT02520115
View directory record Official record
Conditions
Adnexal Mass, Borderline Ovarian Epithelial Tumor, Ovarian Clear Cell Tumor, Ovarian Endometrioid Tumor, Ovarian Neoplasm, Ovarian Serous Tumor, Recurrent Ovarian Carcinoma
Interventions
Dexamethasone, Laboratory Biomarker Analysis, Valproic Acid
Drug · Other
Lead sponsor
Barbara Ann Karmanos Cancer Institute
Other
Eligibility
18 Years and older · Female only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
2
States / cities
Bay City, Michigan • Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Aug 13, 2019 · Synced Jul 22, 2026, 11:55 AM EDT
Completed Not applicable Interventional

Assess Cancer in Ovarian Tumors With Biomarkers.

NCT00436189
View directory record Official record
Conditions
Ovarian Tumor
Interventions
Blood Draw
Procedure
Lead sponsor
Ciphergen Biosystems
Industry
Eligibility
18 Years and older · Female only
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
18
States / cities
Hoover, Alabama • Phoenix, Arizona • Newport Beach, California + 14 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2008 · Synced Jul 22, 2026, 11:55 AM EDT
Recruiting No phase listed Observational

A Diagnostic Test to Evaluate Cancer Risk Before Surgery in Women with an Ovarian Mass

NCT06566716
View directory record Official record
Conditions
Ovarian Neoplasms
Interventions
CleoDX ovarian cancer test
Diagnostic Test
Lead sponsor
Cleo Diagnostics Ltd
Industry
Eligibility
18 Years and older · Female only
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
8
States / cities
Chandler, Arizona • Panama City, Florida • Las Vegas, Nevada + 5 more
Source: ClinicalTrials.gov public record
Updated Feb 3, 2025 · Synced Jul 22, 2026, 11:55 AM EDT
Enrolling by invitation Not applicable Interventional

Clinician Nudge to Referral of Adnexal Masses to Gynecologic Oncology

NCT07078409
View directory record Official record
Conditions
Ovarian Cancer
Interventions
Nudge
Behavioral
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older · Female only
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 21, 2025 · Synced Jul 22, 2026, 11:55 AM EDT
Completed Phase 1 Interventional

Contrast-Enhanced Ultrasonography in Diagnosing Early-Stage Ovarian Cancer in Patients With an Adnexal Mass Undergoing Surgery to Remove the Ovary

NCT00626873
View directory record Official record
Conditions
Ovarian Cancer
Interventions
Definity, medical chart review
Drug · Other
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
21 Years and older · Female only
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
3
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 17, 2017 · Synced Jul 22, 2026, 11:55 AM EDT
Terminated No phase listed Observational

Natera Ovarian Cancer Detection Assay

NCT03485651
View directory record Official record
Conditions
Adnexal Mass
Interventions
Not listed
Lead sponsor
Natera, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 5, 2020 · Synced Jul 22, 2026, 11:55 AM EDT
Completed No phase listed Observational

Mass Response of Tumor Cells as a Biomarker for Rapid Therapy Guidance (TraveraRTGx)

NCT05461430
View directory record Official record
Conditions
Pleural Effusion, Malignant, Ascites, Malignant, Carcinoma, Carcinoma, Hepatocellular, Carcinoma, Renal Cell, Carcinoma, Renal, Carcinoma, Small Cell, Carcinoma, Non-Small-Cell Lung, Carcinoma, Pancreatic Ductal, Carcinoma, Neuroendocrine, Carcinoma, Thymic, Carcinoma, Pancreatic, Carcinoma Breast, Carcinoma, Ovarian, Carcinoma Bladder, Carcinoma of Unknown Primary, Carcinoma of the Head and Neck, Carcinoma of the Oropharynx, Carcinoma of the Larynx, Carcinoma of the Bladder, Carcinoma of Esophagus, Carcinoma of the Nasopharynx, Carcinoma of the Penis, Carcinoma of the Cervix, Carcinoma of the Anus, Carcinoma of the Vulva, Carcinoma of the Appendix, Carcinoma of the Oral Cavity, Cholangiocarcinoma, Melanoma, Mesothelioma, Pancreatic Cancer
Interventions
Not listed
Lead sponsor
Travera Inc
Industry
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Oakland, California
Source: ClinicalTrials.gov public record
Updated Apr 12, 2026 · Synced Jul 22, 2026, 11:55 AM EDT
Recruiting No phase listed Observational

Leveraging Methylated DNA Markers (MDMs) in the Detection of Endometrial Cancer, Ovarian Cancer, and Cervical Cancer

NCT05051722
View directory record Official record
Conditions
Endometrial Cancer, Cervical Cancer, Atypical Endometrial Hyperplasia, Cervical Dysplasia, Adnexal Mass, Ovarian Cancer
Interventions
Vaginal Fluid Collection, Blood Collection
Diagnostic Test
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older · Female only
Enrollment
3,110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
24
States / cities
Phoenix, Arizona • Jacksonville, Florida • Miami, Florida + 20 more
Source: ClinicalTrials.gov public record
Updated Apr 16, 2026 · Synced Jul 22, 2026, 11:55 AM EDT
Completed Early Phase 1 Interventional

Talazoparib in Determining Genetic Effects on Disease Response in Patients With Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

NCT02316834
View directory record Official record
Conditions
Fallopian Tube Serous Adenocarcinoma, High Grade Ovarian Serous Adenocarcinoma, Ovarian Mass, Primary Peritoneal Serous Adenocarcinoma, Stage III Fallopian Tube Cancer AJCC v7, Stage III Ovarian Cancer AJCC v6 and v7, Stage III Primary Peritoneal Cancer AJCC v7, Stage IIIA Fallopian Tube Cancer AJCC v7, Stage IIIA Ovarian Cancer AJCC v6 and v7, Stage IIIA Primary Peritoneal Cancer AJCC v7, Stage IIIB Fallopian Tube Cancer AJCC v7, Stage IIIB Ovarian Cancer AJCC v6 and v7, Stage IIIB Primary Peritoneal Cancer AJCC v7, Stage IIIC Fallopian Tube Cancer AJCC v7, Stage IIIC Ovarian Cancer AJCC v6 and v7, Stage IIIC Primary Peritoneal Cancer AJCC v7, Stage IV Fallopian Tube Cancer AJCC v6 and v7, Stage IV Ovarian Cancer AJCC v6 and v7, Stage IV Primary Peritoneal Cancer AJCC v7
Interventions
Laboratory Biomarker Analysis, BMN 673
Other · Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2022
U.S. locations
6
States / cities
Houston, Texas • Nassau Bay, Texas • Sugar Land, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 23, 2022 · Synced Jul 22, 2026, 11:55 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Study of Insulin Resistance and Endometrial Cancer in Harris County, Texas

NCT00495235
View directory record Official record
Conditions
Endometrial Cancer
Interventions
Questionnaire
Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Female only
Enrollment
147 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2005
U.S. locations
8
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 20, 2014 · Synced Jul 22, 2026, 11:55 AM EDT
Completed No phase listed Observational

New Biomarkers Evaluating Ovarian Cancer

NCT01466049
View directory record Official record
Conditions
Adnexal Mass
Interventions
Not listed
Lead sponsor
Fujirebio Diagnostics, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
280 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
2
States / cities
Wilmington, North Carolina • Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Aug 4, 2014 · Synced Jul 22, 2026, 11:55 AM EDT
Completed No phase listed Observational

Ovarian Cancer Risk Estimation in Patients With Pelvic Mass

NCT00987649
View directory record Official record
Conditions
Adnexal Mass, Ovarian Cancer
Interventions
Not listed
Lead sponsor
Fujirebio Diagnostics, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
512 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
13
States / cities
San Diego, California • Fort Collins, Colorado • Jupiter, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Feb 8, 2011 · Synced Jul 22, 2026, 11:55 AM EDT
Completed Early Phase 1 Interventional

ICG-Enabled Mapping of Ovarian Sentinel Lymph Nodes: A Feasibility Study

NCT04051502
View directory record Official record
Conditions
Ovarian Cancer, Adnexal Mass
Interventions
Method 1: Indocyanine green dye, Method 2: Indocyanine green dye, Method 3: Indocyanine green dye
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Dec 16, 2025 · Synced Jul 22, 2026, 11:55 AM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Energy Balance Interventions in Increasing Physical Activity in Breast Cancer Gene Positive Patients, Lynch Syndrome-Positive Patients, CLL Survivors or High-Risk Family Members

NCT02194387
View directory record Official record
Conditions
Body Mass Index 25 or Greater, BRCA1 Gene Mutation, BRCA2 Gene Mutation, Breast Carcinoma, Cancer Survivor, Chronic Lymphocytic Leukemia, Fatigue, Health Status Unknown, Lynch Syndrome, Ovarian Carcinoma, Overweight
Interventions
Dietary Intervention, Internet-Based Intervention, Laboratory Biomarker Analysis, Questionnaire Administration, Telephone-Based Intervention
Dietary Supplement · Other · Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
337 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 8, 2026 · Synced Jul 22, 2026, 11:55 AM EDT
Active, not recruiting Not applicable Interventional

Nudge to Gynecologic Oncology

NCT06451263
View directory record Official record
Conditions
Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer
Interventions
Nudge
Behavioral
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 18, 2025 · Synced Jul 22, 2026, 11:55 AM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Multifactorial Risk Assessment for Breast & Ovarian Cancer Risk Detection

NCT04668521
View directory record Official record
Conditions
Adnexal Mass, Germline BRCA1 Gene Mutation, Germline BRCA2 Gene Mutation, Hereditary Breast and Ovarian Cancer
Interventions
OVA360
Other
Lead sponsor
Aspira Women's Health
Industry
Eligibility
18 Years and older · Female only
Enrollment
215 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Dec 25, 2023 · Synced Jul 22, 2026, 11:55 AM EDT
Completed No phase listed Observational

Risk of Ovarian Cancer in Patients With a Pelvic Mass

NCT00315692
View directory record Official record
Conditions
Ovarian Cancer
Interventions
Biomarker Assay (CA125 and HE4)
Device
Lead sponsor
Fujirebio Diagnostics, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
566 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
2
States / cities
Malvern, Pennsylvania • Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Nov 7, 2011 · Synced Jul 22, 2026, 11:55 AM EDT
Completed Early Phase 1 Interventional Results available

Contrast-Enhanced Subharmonic Ultrasound Imaging in Improving Characterization of Adnexal Masses in Patients Undergoing Surgery

NCT03297112
View directory record Official record
Conditions
Adnexal Mass
Interventions
Perflutren Lipid Microspheres, Contrast-Enhanced Subharmonic Ultrasound Imaging
Drug · Procedure
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Other
Eligibility
21 Years and older · Female only
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 14, 2025 · Synced Jul 22, 2026, 11:55 AM EDT
Completed No phase listed Observational Results available

Compare Fallopian Tube Cells Collected by Cytuity With Removed Ovarian/Tubal Tissue to Determine Presence of Malignancy

NCT03593681
View directory record Official record
Conditions
Fallopian Tube Cancer, Ovarian Cancer, Ovarian Neoplasms, Ovary Cancer, Fallopian Tube Neoplasms, Fallopian Tube Adenocarcinoma, High Grade Serous Carcinoma, Peritoneal Carcinoma, Peritoneal Neoplasms, Adnexal Mass, Ovarian Diseases
Interventions
Hysteroscopic cell sampling of the fallopian tube
Device
Lead sponsor
Boston Scientific Corporation
Industry
Eligibility
18 Years and older · Female only
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
10
States / cities
San Diego, California • San Francisco, California • Jacksonville, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Jan 19, 2021 · Synced Jul 22, 2026, 11:55 AM EDT
Not listed No phase listed Observational

International Ovarian Tumour Analysis (IOTA) Phase 5

NCT01698632
View directory record Official record
Conditions
Adnexal Masses, Ovarian Cysts, Ovarian Tumors
Interventions
Not listed
Lead sponsor
KU Leuven
Other
Eligibility
18 Years and older · Female only
Enrollment
15,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2021
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Apr 13, 2020 · Synced Jul 22, 2026, 11:55 AM EDT
Completed No phase listed Observational

Clinical Validation of the InterVenn Ovarian CAncer Liquid Biopsy

NCT03837327
View directory record Official record
Conditions
Adnexal Mass, Ovarian Cancer, Pelvic Mass
Interventions
Not listed
Lead sponsor
Venn Biosciences Corporation
Industry
Eligibility
18 Years and older · Female only
Enrollment
1,025 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
10
States / cities
Los Angeles, California • San Jose, California • Sunnyvale, California + 7 more
Source: ClinicalTrials.gov public record
Updated Apr 22, 2024 · Synced Jul 22, 2026, 11:55 AM EDT
Completed No phase listed Observational

EURAD MRI Classification of US Indeterminate Adnexa Lesions

NCT02962596
View directory record Official record
Conditions
Ovarian Tumor
Interventions
ADNEXMR SCORING system
Other
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older · Female only
Enrollment
1,340 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Mar 25, 2020 · Synced Jul 22, 2026, 11:55 AM EDT